Login or sign up
For business
Average ratingGreat
4.0/ 5

Based on 11 reviews

536%
427%
336%
20%
10%
Ask AI

Ask Trustburn about Tengion

Based on 11 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Julie Knepp
Reviews 1

I recently discovered the company while searching for regenerative medicine solutions. 🌱 Their website is so informative and user-friendly, making it easy to learn more about their pioneering work. The team's dedication to advancing ground-breaking technologies is truly inspiring. I appreciated their commitment to transparency and compliance with regulations. The depth of their expertise is evident in the detailed presentations and educational resources available. Their customer support team was incredibly helpful, promptly addressing my inquiries. I found their innovative approach and track record of success very reassuring. Overall, an excellent experience that left me feeling confident in their capabilities. Highly recommend for anyone interested in the cutting-edge field of regenerative medicine. Keep up the great work!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website β€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Tengion

Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells.

The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

Address
3929 Westpoint Blvd
Categories
Biotechnology